Hello,
At out institution, we are revisiting this topic and updating our policies...
Would you mind sharing a policy/guideline related to:
1) Antineoplastic agents for non-oncology indications? (eg methotrexate, IV/PO cyclophosphamide)
2) Biologic agents given for non-oncology indications? (eg rituximab, infliximab)
3) Do you require informed consent for either 1 or 2? If so, do you require re-consenting each year?
Thank you,
Tanya
Tanya John, PharmD, CPPS
Medication Safety Coordinator
Department of Pharmacy
Massachusetts General Hospital
tjohn@partners.org